Nucs AI Forms Medical Advisory Board for AI-Driven Theranostics

Nucs AI has formed a Medical Advisory Board to support the adoption of its AI-powered imaging solutions in cancer care, announced in a press release. The board brings together clinical leaders specializing in radiology, nuclear medicine, oncology, and clinical research.

The advisory group will provide guidance on clinical strategy, study design, and responsible implementation of imaging-based AI in nuclear medicine and oncology. Its members include Jeremie Calais of UCLA, A. Omer Nawaz of AstraZeneca, Francesco Ceci of the European Institute of Oncology, and Murray Becker of Rutgers University.

According to the company, the board will help align technology development with real-world clinical practices as Nucs AI advances validation and wider adoption of its platform. The initiative supports the company’s focus on improving precision theranostics through tools such as DeepPSMA, SelectPSMA, and TrackPSMA for prostate cancer management.